Evaluation of anti oxidative effect of linagliptin on type 2 diabetic patients.

Evaluation of anti oxidative effect of linagliptin on type 2 diabetic patients. - Evaluation of anti oxidative effect of linagliptin on type 2 diabetic patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015308

Enrollment

Registered

2014-10-01

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes

Interventions

5mg of linagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients

Exclusion criteria

Exclusion criteria: Patients who started renin angiotensin system inhibitor, statin, and/or pioglitazon within 1 month

Design outcomes

Primary

Measure	Time frame
Change of MDA-LDL colesterol and urinary 8OHdG	—

Secondary

Measure	Time frame
Change of high sensitive CRP and urinary LFABP	—

Countries

Japan

Contacts

Public ContactHisashi Makino

National cerebral and cardiovascular center Division of endocrinology and metabolism

makinoh@hsp.ncvc.go.jp06-6733-5012

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026